Graphite Bio reports FY2021 net loss $70.8M; GPH101 first patient dosing delayed to H2 2022

LENZ Therapeutics, Inc.

Cash, equivalents, restricted cash $378.7M as of Dec 31, 2021; runway into Q4 2024.
FY2021 net loss $70.8M ($2.45/share); Q4 net loss $18.9M ($0.35/share).
GPH101 Phase 1/2 CEDAR trial: first patient dosing now H2 2022 (COVID-19 impact); initial data 2023.
New programs: GPH102 for beta-thalassemia (IND mid-2024) and early AAT deficiency program.
Appointed Alethia Young as CFO, Christine Garrett as Chief of Staff/SVP Ops; promoted Julia Tran to CPO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.